Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0388 in Patients With Malignant Ascites
NCT07007988Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0388 in malignant ascites (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose limited toxicity at 35 days, Adverse Events and Serious Adverse Events at 2 years and 3 more. Started Apr 2025; status: recruiting.
02
Drugs
SIM0388
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT07007988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007988.